Equities

AC Immune SA

AC Immune SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.06
  • Today's Change-0.11 / -3.47%
  • Shares traded115.66k
  • 1 Year change+5.52%
  • Beta1.2364
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CHF
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments103123198
Total Receivables, Net160.801.40
Total Inventory------
Prepaid expenses6.444.713.02
Other current assets, total------
Total current assets125128203
Property, plant & equipment, net6.887.078.03
Goodwill, net------
Intangibles, net505050
Long term investments0.360.360.36
Note receivable - long term------
Other long term assets------
Total assets183186261
LIABILITIES
Accounts payable1.680.932.00
Accrued expenses119.4217
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.670.550.57
Other current liabilities, total0.140.590.72
Total current liabilities141120
Total long term debt2.832.252.34
Total debt3.502.802.91
Deferred income tax------
Minority interest------
Other liabilities, total5.773.217.10
Total liabilities221729
SHAREHOLDERS EQUITY
Common stock2.091.801.79
Additional paid-in capital475431431
Retained earnings (accumulated deficit)(316)(264)(201)
Treasury stock - common(0.11)(0.12)(0.12)
Unrealized gain (loss)------
Other equity, total(0.05)0.01--
Total equity161169232
Total liabilities & shareholders' equity183186261
Total common shares outstanding998483
Treasury shares - common primary issue5.246.216.22
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.